Why schizophrenia risk reshapes cannabis reward in the brain

This study explores why people with schizophrenia use cannabis at rates up to ten times higher than the general population. Using a genetic mouse model that mimics schizophrenia risk, researchers investigated whether a predisposition to schizophrenia changes how the brain responds to cannabis. They used WIN 55,212-2, a compound that activates CB1 receptors (the primary cannabinoid receptor), to test the rewarding and aversive effects of cannabis-like substances. The key finding: mice genetically predisposed to schizophrenia showed no reward response to low doses of WIN, while normal mice found the same dose pleasurable. This suggests genetic vulnerability to schizophrenia may fundamentally alter how the brain experiences cannabis reward.

The research revealed important sex-based and dose-dependent differences in how genetic schizophrenia risk affects cannabinoid response. Both male and female genetically at-risk mice found high doses of WIN aversive (unpleasant), matching the normal mice. However, males with schizophrenia-risk genetics showed faster development of tolerance to the motor-slowing effects of high-dose WIN, suggesting altered adaptation to repeated exposure. These findings support the hypothesis that shared genetic factors between schizophrenia and cannabis use disorder may explain the high comorbidity, rather than cannabis simply causing schizophrenia or vice versa.

This research has important implications for understanding cannabis use in vulnerable populations. Rather than focusing solely on cannabis as a risk factor, these findings suggest that individuals genetically predisposed to schizophrenia may seek cannabis differently—potentially as a form of self-medication or due to altered reward processing. Understanding these genetic connections could inform better prevention strategies and treatment approaches for people at risk for both conditions.